Seattle Cancer Care Alliance (SCCA) provides comprehensive, leading-edge treatment for people diagnosed with kidney cancers, including renal cell carcinoma, which accounts for 90 percent of kidney tumors in adults.
Genetic changes can be used to help diagnose cancer, understand the risk of recurrence and outlook for survival, and guide therapy decisions. SCCA has a new chromosome genomic array test called OncoScan CGAT to help identify these changes in people with kidney cancer.
Most kidney cancers are initially treated with surgery. Advanced kidney cancer that has returned after surgery or spread to other organs is difficult to treat. Unfortunately, most kidney cancers do not respond to traditional chemotherapy. But there is hope with biologic therapy, or immunotherapy, as well as a new generation of targeted therapies. Currently, the best type of treatment for kidney cancer is participation in a clinical study.
SCCA was formed in part to bring promising new treatments to patients faster. For people with kidney cancer, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of the clinical studies conducted at SCCA and its founding organizations, Fred Hutch and UW Medicine.